AUSTIN (KXAN) — An Anthrax exposure treatment developed at the University of Texas won FDA approval, Monday.
Once inhaled, Anthrax releases a deadly toxin.
The UT scientists engineered an antibody that could deactivate that toxin and prevent people from getting worse.
They worked with a New Jersey-based pharmaceutical company to develop the drug.
It’s now part of the strategic national stockpile, in case of a bio-terror attack.
“Research and education really are combined in institutions like UT Austin, so that you not only have an important practical outcome, the research itself, something of strategic national value, but you also have training of the next generation of scientists,” said Brent Iverson, Professor in the Department of Chemistry.
No live anthrax was used at UT in the drug development process.